贝那普利片联合美托洛尔片治疗高血压合并心力衰竭的临床研究  

Benazepril in combination with metoprolol in the treatment of hypertension in patients with heart failure

作　　者：蔡国强 邹洁 CAI Guo-qiang;ZOU Jie(Department of Pharmacy,Kunshan First People's Hospital,Kunshan 215300,Jiangsu Province,China)

机构地区：[1]昆山市第一人民医院药学部,江苏昆山215300

出　　处：《中国临床药理学杂志》2020年第16期2386-2389,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省自然科学基金资助项目(BK20180467)。

摘　　要：目的研究贝那普利片联合美托洛尔片治疗高血压合并心力衰竭的临床疗效和安全性。方法将86例患者随机分为2组,对照组、试验组各43例,对照组给予贝那普利片10 mg,每日1次。试验组在对照组的基础上加用美托洛尔片100 mg,每日2次。2组均连续治疗12周。比较2组患者的临床疗效、收缩压(SBP)、舒张压(DBP)、左心室射血分数(LVEF)、6 min步行试验(6MWT)、血小板α-颗粒膜蛋白(GMP-140),心肌营养素(CT-1),B型脑钠肽(BNP),血管紧张素Ⅱ(AngⅡ)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95.35%(41例/43例)和81.40%(35例/43例),差异有统计学意义(P<0. 05)。治疗后,试验组和对照组的SBP分别为(122.45±10.36)和(138.63±14.52)mmHg,DBP分别为(78.45±5.96)和(87.96±6.25)mmHg,LVEF分别为(49.54±4.22)%和(41.89±3.96)%,6MWT分别为(367.23±50.44)和(332.63±45.85)m,GMP-140分别为(10.74±2.16)和(14.98±2.96)ng·mL-1,CT-1分别为(110.24±41.46)和(138.64±45.84)ng·L-1,BNP分别为(168.53±14.74)和(238.23±19.54)ng·L-1,AngⅡ分别为(70.54±6.41)和(81.56±7.23)ng·L-1,差异均有统计学意义(均P<0. 05)。对照组和试验组的药物不良反应主要有胃肠道不适,干咳,低血压及心律失常,对照组和试验组的总药物不良反应发生率分别为11.63%(5例/43例)和13.95%(6例/43例),差异无统计学意义(P>0.05)。结论贝那普利片与美托洛尔片联合用于高血压合并心力衰竭可降低GMP-140,CT-1,BNP,AngⅡ的表达水平,改善LVEF及血压水平,且安全性高。Objective To study the clinical efficacy of benazepril combined with metoprolol in the treatment of hypertension in patients with heart failure. Methods 86 patients were randomly divided into two groups, the control group and the treatment group, each with 43 patients. The control group was given 10 mg of benazepril once daily. The treatment group was given 100 mg of metoprolol tablets twice daily on the basis of the control group. Both groups were treated for 12 weeks. The clinical efficacy of two groups patients, systolic blood pressure(SBP), diastolic blood pressure(DBP), left ventricular ejection fraction(LVEF), 6 min walk test(6 MWT), platelet alpha particles membrane protein(GMP-140), myocardial nutrients(CT), b-type brain natriuretic peptide(BNP),angiotensin Ⅱ(Ang Ⅱ) levels,and drug adverse drug reaction were compared.Results After treatment,the total effective rates of the treatment group and control group were 95. 35%(41 cases/43 cases) and 81. 40%(35 cases/43 cases),respectively,with statistically significant difference(P < 0. 05). After treatment,SBP in the treatment group and control group were(122. 45 ± 10. 36) and(138. 63 ± 14. 52) mmH g,DBP were(78. 45 ± 5. 96) and(87. 96 ± 6. 25) mmH g,LVEF were(49. 54 ± 4. 22) % and(41. 89 ± 3. 96) %,6 MWT were(367. 23 ± 50. 44) and(332. 63 ± 45. 85) m,GMP-140 were(10. 74 ± 2. 16) and(14. 98 ± 2. 96)ng·mL-1,CT-1 were(110. 24 ± 41. 46) and(138. 64 ± 45. 84) ng·L-1,BNP were(168. 53 ± 14. 74) and(238. 23 ± 19. 54) ng · L-1,Ang Ⅱ were(70. 54 ± 6. 41) and(81. 56 ± 7. 23) ng · L-1,with statistically significant differences(all P < 0. 05). The main adverse drug reactions in the control group and the test group were gastrointestinal discomfort,dry cough,hypotension and arrhythmia. The total adverse drug reaction rates in the control group and the treatment group were 11. 63%(5 cases/43 cases) and 13. 95%(6 cases/43 cases),respectively,with no statistically significant difference(P > 0. 05). Conclusion Benazepril in combiantion with metoprolol ca

关 键 词：贝那普利 美托洛尔 高血压 心力衰竭 血小板Α-颗粒膜蛋白 

分 类 号：R97[医药卫生—药品]